Learn more about whether ACADIA Pharmaceuticals Inc. or Legend Biotech Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Fabrice is a deeply experienced global pharmaceutical and biotechnology executive, who brings a wealth of profound global expertise and experience, across the entire biopharmaceutical value chain ...

XtalPi Holdings, an artificial intelligence (AI) drug discovery firm based in the Greater Bay Area, is changing the biopharmaceutical ... to 90 per cent from 20 to 30 per cent, according to ...

Zacks Research boosted their Q2 2025 earnings per share estimates for Gilead Sciences in a report issued on Thursday, January ...

Chronic Pain, that persists beyond the usual recovery period or occurs along with a chronic health condition, such as arthritis. The rising prevalence of chronic pain drives market growth by ...

Cathie Wood is piling into little-known AI stock Tempus AI, Inc. (NASDAQ:TEM), amassing about 600,000 shares across multiple ...

(MENAFN- Investor Brand Network) AEON Biopharma (NYSE: AEON) , a clinical-stage biopharmaceutical company ... AEON secured approximately $20.0 million in gross proceeds from the offering, of ...

SAN FRANCISCO (Reuters) - The biopharmaceutical industry is aiming for a 2025 reversal of last year's slump in investor returns but remains wary over what President-elect Donald Trump's priorities ...

Plans to Advance Iopofosine I 131 Internally, Through Strategic Partnerships and Other Approaches; Finalizing Confirmatory Study and Pathway for US FDA Accelerated Approval and EMA Prime Marketing ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.